Skip to main content

Month: March 2026

CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update

– Announced Positive Data from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) – – FDA interactions targeted for mid-year with goal to align on potential Varseta-M registrational trial design in late line CRC – – Varseta-M Phase 1 study evaluating combination with bevacizumab initiated; Phase 1b/2 chemotherapy combination study to be initiated by the end of 2026 – – Initial CX-801 PROBODY Interferon-alpha-2b Phase 1 combination data with KEYTRUDA® (pembrolizumab) in melanoma expected by the end of 2026 – – Company to host conference call today at 8 a.m. ET / 5 a.m. PT – SOUTH SAN FRANCISCO, Calif., March 16, 2026 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in...

Continue reading

Flagship Communities Real Estate Investment Trust Announces March 2026 Cash Distribution

Not for distribution to U.S. newswire services or dissemination in the United States. TORONTO, March 16, 2026 (GLOBE NEWSWIRE) — Flagship Communities Real Estate Investment Trust (“Flagship” or the “REIT”) (TSX:MHC.U) (TSX:MHC.UN) today announced a cash distribution of US$0.0545 per REIT unit for the month of March 2026, representing US$0.654 per REIT unit on an annualized basis. Payments will be made on or about April 15, 2026, to unitholders of record as of the close of business on March 31, 2026. Distributions paid to Canadian unitholders (and other non-U.S. unitholders) generally will be subject to U.S. withholding tax. Unitholders should consult their own tax advisors for advice with respect to the tax consequences of receiving a distribution from the REIT in their own circumstance. About Flagship Communities Real Estate Investment...

Continue reading

MONUMENTAL ENERGY ANNOUNCES COMMERCIAL PRODUCTION AT WAIHAPA H1

ALL 7 PERFORATIONS ACHIEVED SIGNIFICANT OIL PRODUCTION AND ASSOCIATED GASVancouver, British Columbia, March 16, 2026 (GLOBE NEWSWIRE) —  Monumental Energy Corp. (“Monumental” or the “Company”) (TSX-V: MNRG; FSE: ZA6; OTCQB: MNMRF) is pleased to announce the successful restart of commercial production from all 7 perforations in the Mount Messenger formation located near the top of the Waihapa H1 well. The Waihapa H1 well is located within 100 meters of the Waihapa production facility and oil is being sent through the pipeline into a holding tank at the facility.  Monumental and New Zealand Energy Corp. (“NZEC”) entered into a funding agreement (see the Company’s news releases dated January 12, 2026, March 5, 2026 and March 10, 2026), which enables Monumental to participate in mutually agreed-upon appraisal and development workover...

Continue reading

Landsbankinn hf.: End of repurchase period

On 25 February 2026, Landsbankinn announced that the Bank offered to repurchase shares from shareholders during the period from and including 2 March 2026 up to and including 13 March 2026. In total, Landsbankinn repurchased 4,594,709 own shares during the period from and including 2 March 2026 up to and including 13 March 2026, at a price of 14.56 per share, for a total consideration of ISK 66,898,959. Prior to commencement of repurchases, Landsbankinn held 385.4 million own shares. Following the above-mentioned transactions, the Bank holds 390 million own shares, corresponding to approximately 1.6% of issued share capital in the Bank. The total number of outstanding shares in the Bank is 23,615 million shares. Repurchases during the period were capped at 48 million shares. For further information contact: Rúnar Pálmason, Public Relations,...

Continue reading

Brookfield Business Partners Announces Closing Date of Corporate Simplification

BROOKFIELD, NEWS, March 16, 2026 (GLOBE NEWSWIRE) — Brookfield Business Partners L.P. (“BBU”) and Brookfield Business Corporation (“BBUC”) announced today that they have received all required approvals to complete the previously announced corporate simplification to convert into one publicly traded Canadian corporation. “Today represents an important milestone in the continued growth and evolution of our business as we near the completion of simplifying our corporate structure,” said Anuj Ranjan, CEO of Brookfield Business Partners. “We expect the benefits of converting into a single listed corporate entity – including greater index inclusion and improved trading liquidity will help broaden our global investor base and support our continued focus on creating long-term value for our shareholders.” The court-approved plan of arrangement...

Continue reading

AirSculpt Technologies Announces Its Intent to Delay the Filing of its Annual Report and Provides Business Update

Preliminary Fiscal Year 2025 Revenue of $151.8 Million Refreshed Marketing Strategy Delivers Positive Same-Store Sales in February 2026 Strong Balance Sheet and Enhanced Liquidity MIAMI BEACH, Fla., March 16, 2026 (GLOBE NEWSWIRE) — AirSculpt Technologies, Inc. (NASDAQ:AIRS) (“AirSculpt” or the “Company”), a national provider of premium body contouring procedures, today announced that it expects to file a Form 12b-25 with the U.S. Securities and Exchange Commission (the “SEC”) on or about March 16, 2026, providing the Company a 15-day extension to file its annual report for the fiscal year ended December 31, 2025 on Form 10-K (the “Annual Report”). The extension will give the Company additional time to complete the classification of its inter-company transactions and balances. The Company intends to file the Annual Report as soon...

Continue reading

Zacatecas Silver Receives Drill Permit for El Cristo, Supporting 2026 Drill Program Aimed at Increasing Existing Silver Resource at the Zacatecas Silver Project

VANCOUVER, British Columbia, March 16, 2026 (GLOBE NEWSWIRE) — Zacatecas Silver Corp. (TSXV: ZAC | OTCQB: ZCTSF | FRA: 7TV) (“Zacatecas Silver” or the “Company”) is pleased to announce that it has received the necessary drill permit from Mexico’s environmental authority, Secretaría de Medio Ambiente y Recursos Naturales (“SEMARNAT”), for the El Cristo vein system, a priority target at the Company’s wholly owned Zacatecas Silver Project in Zacatecas State, Mexico. Following review of the Company’s Informe Preventivo environmental filing, SEMARNAT confirmed that the proposed exploration program may proceed under the terms outlined in the filing. The permit approval marks a major milestone ahead of the Company’s planned 2026 drill campaign, designed to test high-priority targets at both the El Cristo and Panuco vein systems and to...

Continue reading

Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia

– Bempedoic Acid Receives Strongest Endorsement from AHA/ACC Multisociety Guideline for Patients with Statin Intolerance and in Primary and Secondary Prevention Patients with Severe Hypercholesterolemia – – Bempedoic Acid Receives Equal Positioning with PCSK9 mAb and Ezetimibe After Statins for High-Risk Primary Prevention and Clinical ASCVD Not at Very High-Risk Patients – – Guideline Recognition of Early Combination Lipid-Lowering Therapy and Reintroduction of LDL-C Goals Affirms ‘Lower for Longer is Better’ Approach to Cardiovascular Risk Reduction – ANN ARBOR, Mich., March 16, 2026 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) welcomed the inclusion of bempedoic acid for LDL-C lowering and cardiovascular risk reduction in the 2026 Americal College of Cardiology (ACC)/American Heart Association (AHA) Multisociety Guideline on the...

Continue reading

Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio

Financing demonstrates conviction in oligomer-selective approach and follows strong preclinical data, including in vitro, in vivo and non-human primate study results, that support development candidates in Acumen’s transferrin-receptor targeting Enhanced Brain Delivery (EBD™) program Candidates exceeded key preclinical criteria, demonstrating elevated brain exposure in non-human primates up to 40-fold over native antibodies, low risk of anemia, and robust stability profiles to enable subcutaneous administration Lead clinical candidate IND targeted for mid-2027NEWTON, Mass., March 16, 2026 (GLOBE NEWSWIRE) —  Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid b oligomers (AβOs) for the treatment...

Continue reading

Nova Winter Freight Haul Underway

Anchorage Alaska, March 16, 2026 (GLOBE NEWSWIRE) — Nova Minerals Limited (“Nova” or the “Company”) (NASDAQ: NVA) (ASX: NVA) (FRA: QM3) ) is pleased to announce that the mobilization of heavy equipment to the Estelle Project is underway via the Company’s winter snow road, approximately 150km from Willow. (Figure 1). Ideal winter conditions allowed snow road construction to commence in early December, which involved pre-packing snow, water-flooding for ice thickening at major river crossings, and minor brush clearing. This winter has delivered near perfect snow road conditions with exceptionally cold temperatures that are favorable for the construction of ice bridges over 1.5m (5ft) thick. These bridges are capable of supporting freight loads well over 100,000lb (45,000kg) while preserving a hard snowpack base. To watch a video of...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.